JX401, a p38α inhibitor containing a 4-benzylpiperidine motif, identified via a novel screening system in yeast

Molecular Pharmacology

Volumn 70, Issue 4, 2006, Pages 1395-1405

  Friedmann, Yael ^a   Shriki, Anat ^a   Bennett, Estelle R ^a   Golos, Stella ^c   Diskin, Ron ^b   Marbach, Irit ^b   Bengal, Eyal ^c   Engelberg, David ^a,b  

^a Jexys Pharmaceuticals Ltd   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

4 BENZYLPIPERIDINE; JX 401; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; P 38 ALPHA PROTEIN; PIPERIDINE DERIVATIVE; PROTEIN; UNCLASSIFIED DRUG; MAPK PHOSPHATASE; MITOGEN ACTIVATED PROTEIN KINASE 14; PROTEIN TYROSINE PHOSPHATASE;

ARTICLE; CONTROLLED STUDY; GROWTH RATE; GROWTH RETARDATION; HIGH THROUGHPUT SCREENING; INFLAMMATORY DISEASE; MAMMAL CELL; MEMBRANE PERMEABILITY; MOLECULAR LIBRARY; NONHUMAN; PRIORITY JOURNAL; YEAST; ANIMAL; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; CHEMICAL STRUCTURE; DRUG ANTAGONISM; DRUG SCREENING; ENZYME SPECIFICITY; EVALUATION; METABOLISM; MYOBLAST; PHENOTYPE; PHOSPHORYLATION; PHYSIOLOGY; PROTEIN MOTIF; RAT; TIME;

AMINO ACID MOTIFS; ANIMALS; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; DRUG EVALUATION, PRECLINICAL; MITOGEN-ACTIVATED PROTEIN KINASE 14; MOLECULAR STRUCTURE; MYOBLASTS; PHENOTYPE; PHOSPHORYLATION; PROTEIN-TYROSINE-PHOSPHATASE; RATS; SUBSTRATE SPECIFICITY; TIME FACTORS; YEASTS;

EID: 33748929692     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.106.022962     Document Type: Article

References (61)

1. Adams RH, Porras A, Alonso G, Jones M, Vintersten K, Panelli S, Valladares A, Perez L, Klein R, and Nebreda AR (2000) Essential role of p38alpha MAP kinase in placental but not embryonic cardiovascular development. Mol Cell 6:109-116.
2. Bach S, Talarek N, Andrieu T, Vierfond JM, Mettey Y, Galons H, Dormont D, Meijer L, Cullin C, and Blondel M (2003) Isolation of drugs active against mammalian prions using a yeast-based screening assay. Nat Biotechnol 21: 1075-1081.
3. Behr TM, Berova M, Doe CP, Ju H, Angermann CE, Boehm J, and Willette RN (2003) p38 mitogen-activated protein kinase inhibitors for the treatment of chronic cardiovascular disease. Curr Opin Investig Drugs 4:1059-1064.
4. Bell M, Capone R, Pashtan I, Levitzki A, and Engelberg D (2001) Isolation of hyperactive mutants of the MAPK p38/Hog1 that are independent of MAPK kinase activation. J Biol Chem 276:25351-25358.
5. Benhar M, Dalyot I, Engelberg D, and Levitzki A (2001) Enhanced ROS production in oncogenically transformed cells potentiates c-Jun N-terminal kinase and p38 mitogen-activated protein kinase activation and sensitization to genotoxic stress. Mol Cell Biol 21:6913-6926.
6. Blundell TL (1996) Structure-based drug design. Nature (Lond) 384:23-26.
7. Blundell TL, Jhoti H, and Abell C (2002) High-throughput crystallography for lead discovery in drug design. Nat Rev Drug Discov 1:45-54.
8. Bogoyevitch MA and Court NW (2004) Counting on mitogen-activated protein kinases-ERKs 3, 4, 5, 6, 7 and 8. Cell Signal 16:1345-1354.
9. Brewster JL, de Valoir T, Dwyer ND, Winter E, and Gustin MC (1993) An osmosensing signal transduction pathway in yeast. Science (Wash DC) 259:1760-1763.
10. Broach JR and Thorner J (1996) High-throughput screening for drug discovery. Nature (Lond) 384:14-16.
11. Bulavin DV and Fornace AJ Jr (2004) p38 MAP kinase's emerging role as a tumor suppressor. Adv Cancer Res 92:95-118.
12. Colicelli J, Birchmeier C, Michaeli T, O'Neill K, Riggs M, and Wigler M (1989) Isolation and characterization of a mammalian gene encoding a high-affinity cAMP phosphodiesterase. Proc Natl Acad Sci USA 86:3599-3603.
13. Crawley JB, Rawlinson L, Lali FV, Page TH, Saklatvala J, and Foxwell BM (1997) T cell proliferation in response to interleukins 2 and 7 requires p38MAP kinase activation. J Biol Chem 272:15023-15027.
14. Cuenda A and Cohen P (1999) Stress-activated protein kinase-2/p38 and a rapamycin-sensitive pathway are required for C2C12 myogenesis. J Biol Chem 274:4341-4346.
15. Cuenda A, Rouse J, Doza YN, Meier R, Cohen P, Gallagher TF, Young PR, and Lee JC (1995) SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett 364:229-233.
16. Davies TG, Pratt DJ, Endicott JA, Johnson LN, and Noble ME (2002) Structure-based design of cyclin-dependent kinase inhibitors. Pharmacol Ther 93:125-133.
17. Diskin R, Askari N, Capone R, Engelberg D, and Livnah O (2004) Active mutants of the human p38alpha mitogen-activated protein kinase. J Biol Chem 279:47040-47049.
18. Engelberg D (2004) Stress-activated protein kinases-tumor suppressors or tumor initiators? Semin Cancer Biol 14:271-282.
19. English JM and Cobb MH (2002) Pharmacological inhibitors of MAPK pathways. Trends Pharmacol Sci 23:40-45.
20. Esteva FJ, Sahin AA, Smith TL, Yang Y, Pusztai L, Nahta R, Buchholz TA, Buzdar AU, Hortobagyi GN, and Bacus SS (2004) Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer 100:499-506.
21. Gallagher TF, Seibel GL, Kassis S, Laydon JT, Blumenthal MJ, Lee JC, Lee D, Boehm JC, Fier-Thompson SM, Abt JW, et al. (1997) Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase. Bioorg Med Chem 5:49-64.
22. Goehring R, Luedtke GR, Mavunkel BJ, Chakravarty S, Dugar S, Schreiner GF, Liu DY, and Lewicki JA (2002), inventors; Scios, Inc., assignee. Inhibitors of p38-alpha kinase. U.S. Patent 6,410,540, B1. 2002 June 25.
23. Gredinger E, Gerber AN, Tamir Y, Tapscott SJ, and Bengal E (1998) Mitogen-activated protein kinase pathway is involved in the differentiation of muscle cells. J Biol Chem 273:10436-10444.
24. Gustin MC, Albertyn J, Alexander M, and Davenport K (1998) MAP kinase pathways in the yeast Saccharomyces cerevisiae. Microbiol Mol Biol Rev 62:1264-1300.
25. Han J, Lee JD, Bibbs L, and Ulevitch RJ (1994) A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science (Wash DC) 265:808-811.
26. Hogan JC Jr (1996) Directed combinatorial chemistry. Nature (Lond) 384:17-19.
27. Hommes D, van den Blink B, Plasse T, Bartelsman J, Xu C, Macpherson B, Tytgat G, Peppelenbosch M, and Van Deventer S (2002) Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology 122:7-14.
28. Kirsch DR (1993) Development of improved cell-based assays and screens in Saccharomyces through the combination of molecular and classical genetics. Curr Opin Biotechnol 4:543-552.
29. Kumar S, Boehm J, and Lee JC (2003) p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2:717-726.
30. Kumar S, Jiang MS, Adams JL, and Lee JC (1999) Pyridinylimidazole compound SB 203580 inhibits the activity but not the activation of p38 mitogen-activated protein kinase. Biochem Biophys Res Commun 263:825-831.
31. Kumar S, McLaughlin MM, McDonnell PC, Lee JC, Livi GP, and Young PR (1995) Human mitogen-activated protein kinase CSBP1, but not CSBP2, complements a hog1 deletion in yeast. J Biol Chem 270:29043-29046.
32. Kummer JL, Rao PK, and Heidenreich KA (1997) Apoptosis induced by withdrawal of trophic factors is mediated by p38 mitogen-activated protein kinase. J Biol Chem 272:20490-20494.
33. Kyriakis JM and Avruch J (2001) Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol Rev 81:807-869.
34. Lee JC, Kumar S, Griswold DE, Underwood DC, Votta BJ, and Adams JL (2000) Inhibition of p38 MAP kinase as a therapeutic strategy. Immunopharmacology 47:185-201.
35. Lewis TS, Shapiro PS, and Ahn NG (1998) Signal transduction through MAP kinase cascades. Adv Cancer Res 74:49-139.
36. Lum PY, Armour CD, Stepaniants SB, Cavet G, Wolf MK, Butler JS, Hinshaw JC, Garnier P, Prestwich GD, Leonardson A, et al. (2004) Discovering modes of action for therapeutic compounds using a genome-wide screen of yeast heterozygotes. Cell 116:121-137.
37. Montalibet J and Kennedy BP (2004) Using yeast to screen for inhibitors of protein tyrosine phosphatase 1B. Biochem Pharmacol 68:1807-1814.
38. Munder T and Hinnen A (1999) Yeast cells as tools for target-oriented screening. Appl Microbiol Biotechnol 52:311-320.
39. New L and Han J (1998) The p38 MAP kinase pathway and its biological function. Trends Cardiovasc Med 8:220-228.
40. Noble ME, Endicott JA, and Johnson LN (2004) Protein kinase inhibitors: insights into drug design from structure. Science (Wash DC) 303:1800-1805.
41. Olson JM and Hallahan AR (2004) p38 MAP kinase: a convergence point in cancer therapy. Trends Mol Med 10:125-129.
42. Ono K and Han J (2000) The p38 signal transduction pathway: activation and function. Cell Signal 12:1-13.
43. Pausch MH (1997) G-protein-coupled receptors in Saccharomyces cerevisiae: high-throughput screening assays for drug discovery. Trends Biotechnol 15: 487-494.
44. Puri PL, Wu Z, Zhang P, Wood LD, Bhakta KS, Han J, Feramisco JR, Karin M, and Wang JY (2000) Induction of terminal differentiation by constitutive activation of p38 MAP kinase in human rhabdomyosarcoma cells. Genes Dev 14:574-584.
45. Redman AM, Johnson JS, Dally R, Swartz S, Wild H, Paulsen H, Caringal Y, Gunn D, Renick J, Osterhout M, et al. (2001) p38 kinase inhibitors for the treatment of arthritis and osteoporosis: thienyl, furyl, and pyrrolyl ureas. Bioorg Med Chem Lett 11:9-12.
46. Schultz RM (2003) Potential of p38 MAP kinase inhibitors in the treatment of cancer. Prog Drug Res 60:59-92.
47. Sikorski RS and Hieter P (1989) A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae. Genetics 122:19-27.
48. Silverman L, Campbell R, and Broach JR (1998) New assay technologies for high-throughput screening. Curr Opin Chem Biol 2:397-403.
49. Tamura K, Sudo T, Senftleben U, Dadak AM, Johnson R, and Karin M (2000) Requirement for p38alpha in erythropoietin expression: a role for stress kinases in erythropoiesis. Cell 102:221-231.
50. Toda T, Uno I, Ishikawa T, Powers S, Kataoka T, Broek D, Cameron S, Broach J, Matsumoto K, and Wigler M (1985) In yeast, RAS proteins are controlling elements of adenylate cyclase. Cell 40:27-36.
51. Tugendreich S, Perkins E, Couto J, Barthmaier P, Sun D, Tang S, Tulac S, Nguyen A, Yeh E, Mays A, et al. (2001) A streamlined process to phenotypically profile heterologous cDNAs in parallel using yeast cell-based assays. Genome Res 11:1899-1912.
52. van Hille B and Hill BT (1998) Yeast cells expressing differential levels of human or yeast DNA topoisomerase II: a potent tool for identification and characterization of topoisomerase II-targeting antitumour agents. Cancer Chemother Pharmacol 42:345-356.
53. Warmka J, Hanneman J, Lee J, Amin D, and Ota I (2001) Ptc1, a type 2C Ser/Thr phosphatase, inactivates the HOG pathway by dephosphorylating the mitogen-activated protein kinase Hog1. Mol Cell Biol 21:51-60.
54. Wu Z, Woodring PJ, Bhakta KS, Tamura K, Wen F, Feramisco JR, Karin M, Wang JY, and Puri PL (2000) p38 and extracellular signal-regulated kinases regulate the myogenic program at multiple steps. Mol Cell Biol 20:3951-3964.
55. Yaakov G, Bell M, Hohmann S, and Engelberg D (2003) Combination of two activating mutations in one HOG1 gene forms hyperactive enzymes that induce growth arrest. Mol Cell Biol 23:4826-4840.
56. Yaffe D and Saxel O (1977) A myogenic cell line with altered serum requirements for differentiation. Differentiation 7:159-166.
57. Young KH, Wang Y, Bender C, Ajit S, Ramirez F, Gilbert A, and Nieuwenhuijsen BW (2004) Yeast-based screening for inhibitors of RGS proteins. Methods Enzymol 389:277-301.
58. Young PR, McLaughlin MM, Kumar S, Kassis S, Doyle ML, McNulty D, Gallagher TF, Fisher S, McDonnell PC, Carr SA, et al. (1997) Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase bind in the ATP site. J Biol Chem 272:12116-12121.
59. Zaks-Makhina E, Kim Y, Aizenman E, and Levitan ES (2004) Novel neuroprotective K+ channel inhibitor identified by high-throughput screening in yeast. Mol Pharmacol 65:214-219.
60. Zetser A, Gredinger E, and Bengal E (1999) p38 mitogen-activated protein kinase pathway promotes skeletal muscle differentiation. Participation of the Mef2c transcription factor. J Biol Chem 274:5193-5200.
61. Zhang X, Smith DL, Meriin AB, Engemann S, Russel DE, Roark M, Washington SL, Maxwell MM, Marsh JL, Thompson LM, et al. (2005) A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo. Proc Natl Acad Sci USA 102:892-897.